Journal of Clinical Oncology · 2001 · 246 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyMalignant NeoplasmsPharmacodynamics Of Anticancer DrugsPharmacokinetics Of Anticancer DrugsSarcoma PharmacotherapySoft Tissue SarcomasToxicity ManagementClinical Trials In SarcomaDose-rate EffectsGemcitabine-based TherapyLeiomyosarcoma TherapyPartial Response AssessmentPhase Ii Clinical TrialsPhase Ii InvestigationSoft Tissue Sarcoma Treatment
PURPOSE: To evaluate the efficacy, toxicity, and optimal dose rate of gemcitabine in adult patients with advanced soft tissue sarcomas (STS) by comparing levels of gemcitabine triphosphate (GTP) in peripheral-blood mononuclear cells (PBMCs) of patients receiving two different dose rates. PATIENTS AND METHODS: Fifty-six assessable patients with STS (17 gastrointestinal [GI] leiomyosarcomas and 39 other histologies) were treated on a two-arm phase II study. Gemcitabine was given at 1 g/m2 as a 30-minute infusion weekly for up to 7 weeks followed by 1 week of rest and reassessment of tumor. Subsequent cycles were given at 1 g/m2 weekly for 3 weeks followed by 1 week of rest. Nine patients underwent cellular pharmacologic studies at two different dose rates (1 g/m2 over a standard 30-minute infusion on week 1 and over pharmacologically based infusion of 150 minutes on week 2) to evaluate GTP levels in PBMCs. RESULTS: Seven partial responses were noted among 39 patients, for an overall response rate of 18% (95% confidence interval, 7% to 29%). Median duration of response was 3.5 months (range, 2 to 13 months). Four of 10 patients with non-GI leiomyosarcomas achieved a partial response. No objective responses were noted in 17 patients with GI leiomyosarcomas. One patient had a mixed response. Median time to progression for all patients (both arms) was 3 months; median survival was 13.9 months. Treatment was generally well tolerated. Comparison of cellular pharmacology demonstrated a significant 1.4-fold increase in the concentration of GTP with the 150-minute infusion. CONCLUSION: Given the limited therapeutic armamentarium for STS, the activity of gemcitabine is encouraging. Its potential for combination therapy in the salvage setting should be studied with pharmacologically guided fixed dose-rate infusion.
17
Robert T. Greenlee, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 2000 · 3.9K citations · Full text
Optimal two-stage designs for phase II clinical trials
Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Peng Huang, Sherri Chubb, Larry W. Hertel et al. · PubMed · 1991 · 884 citations